The University of Southampton
University of Southampton Institutional Repository

Type 2 diabetes, psoriasis and thiazolidinediones

Type 2 diabetes, psoriasis and thiazolidinediones
Type 2 diabetes, psoriasis and thiazolidinediones
Thiazolidinediones, synthetic ligands for the peroxisome proliferator-activated receptor-? (PPAR-?) receptor, are insulin-sensitizing drugs licensed for use in selected patients with type 2 diabetes mellitus. The potential therapeutic applications of the thiazolidinediones extend to other clinical specialities such as dermatology. Rosiglitazone and pioglitazone are being evaluated for the treatment of psoriasis. Type 2 diabetes and psoriasis may coexist prompting speculation that dual benefits might accrue for patients with both conditions. A recent open pilot study suggests that oral pioglitazone may be beneficial for moderate chronic plaque psoriasis. However, changes in antidiabetic medication must be made in the knowledge of the cautions and contraindications to oral agents as well as the impact on metabolic control. Further studies are required before the use of thiazolidinediones for psoriasis can be advocated.
362-363
Krentz, A.J.
9f3c00da-2737-4e5f-9403-e803af2744f6
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88
Krentz, A.J.
9f3c00da-2737-4e5f-9403-e803af2744f6
Friedmann, P.S.
d50bac23-f3ec-4493-8fa0-fa126cbeba88

Krentz, A.J. and Friedmann, P.S. (2006) Type 2 diabetes, psoriasis and thiazolidinediones. International Journal of Clinical Practice, 60 (3), 362-363. (doi:10.1111/j.1368-5031.2005.00765.x).

Record type: Article

Abstract

Thiazolidinediones, synthetic ligands for the peroxisome proliferator-activated receptor-? (PPAR-?) receptor, are insulin-sensitizing drugs licensed for use in selected patients with type 2 diabetes mellitus. The potential therapeutic applications of the thiazolidinediones extend to other clinical specialities such as dermatology. Rosiglitazone and pioglitazone are being evaluated for the treatment of psoriasis. Type 2 diabetes and psoriasis may coexist prompting speculation that dual benefits might accrue for patients with both conditions. A recent open pilot study suggests that oral pioglitazone may be beneficial for moderate chronic plaque psoriasis. However, changes in antidiabetic medication must be made in the knowledge of the cautions and contraindications to oral agents as well as the impact on metabolic control. Further studies are required before the use of thiazolidinediones for psoriasis can be advocated.

This record has no associated files available for download.

More information

Published date: 2006

Identifiers

Local EPrints ID: 27210
URI: http://eprints.soton.ac.uk/id/eprint/27210
PURE UUID: 463b4bd9-f5a1-40b5-bc16-ed91133fb05a

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Mar 2024 07:16

Export record

Altmetrics

Contributors

Author: A.J. Krentz
Author: P.S. Friedmann

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×